Magungunan Coronavirus (COVID-19): an yarda da su kuma suna kan karatu

Wadatacce

• Magunguna da aka yarda dasu don kwayar cutar
• Magungunan da ake nazari
• 1. Ivermectin
• 2. Maganin Plitidepsin
• 3. Remdisivir
• 4. Dexamethasone
• 5. Hydroxychloroquine da chloroquine
• 6. Colchicine
• 7. Mefloquine
• 8. Tocilizumab
• 9. Plasma mai naƙasa
• 10. Avifavir
• 11. Baricitinib
• 12. EXO-CD24
• Zaɓuɓɓukan maganin gargajiya don coronavirus

A halin yanzu, babu wasu sanannun kwayoyi da zasu iya kawar da sabon kwayar cutar daga jiki kuma, saboda wannan dalili, a mafi yawan lokuta, ana yin magani tare da measuresan matakan da magungunan da zasu iya sauƙaƙa alamun cutar COVID-19.

Al'amura masu sauki, tare da alamun kamannin mura na yau da kullun, ana iya magance su a gida tare da hutawa, shayarwa da amfani da magungunan zazzabi da masu magance ciwo. Batutuwa mafi tsanani, wanda mafi tsananin alamun cututtuka da rikice-rikice irin su ciwon huhu suka bayyana, ana buƙatar kulawa da su a lokacin shiga asibiti, sau da yawa a Intungiyoyin Kulawa Na Musamman (ICU), don tabbatarwa, musamman, isasshen gudanarwar iskar oxygen da sa ido kan alamu masu mahimmanci.

Duba ƙarin cikakkun bayanai game da maganin COVID-19.

Baya ga magunguna, ana yin nazarin wasu alluran rigakafin COVID-19, samarwa da rarraba su. Waɗannan alurar rigakafin sun yi alƙawarin hana kamuwa da cutar COVID-19, amma kuma suna da alama suna rage ƙarfin alamun lokacin da kamuwa da cutar ta faru. Mafi kyawun fahimtar wane maganin alurar rigakafi game da COVID-19 akwai, yadda suke aiki da yiwuwar sakamako mai illa.

Magunguna da aka yarda dasu don kwayar cutar

Magungunan da aka yarda da su don maganin kwayar cutar, ta Anvisa da Ma'aikatar Lafiya, su ne waɗanda ke iya sauƙaƙa alamun kamuwa da cutar, kamar su:

• Magungunan rigakafi: don rage yawan zafin jiki da yaƙi da zazzaɓi;
• Masu rage zafi: don taimakawa ciwon tsoka cikin jiki;
• Maganin rigakafi: don magance yiwuwar cututtukan ƙwayoyin cuta waɗanda zasu iya tashi tare da COVID-19.

Waɗannan magunguna ya kamata a yi amfani dasu kawai a ƙarƙashin jagorancin likita kuma, kodayake an yarda da su don maganin sabon coronavirus, ba za su iya kawar da ƙwayoyin cutar daga jiki ba, amma ana amfani da su ne kawai don sauƙaƙe alamomin da inganta jin daɗin mutumin da ya kamu da cutar.

Magungunan da ake nazari

Baya ga magungunan da ke taimakawa wajen magance alamomin, ƙasashe da dama suna ci gaba da karatu a cikin dabbobin dakin gwaje-gwaje da marasa lafiyar da ke kamuwa da cutar don ƙoƙarin gano wani magani da zai iya kawar da ƙwayar cutar daga jiki.

Bai kamata a yi amfani da magungunan da ake nazarin ba ba tare da jagorancin likita ba, ko kuma hanyar kariya daga kamuwa da cuta, saboda suna iya haifar da illa daban-daban kuma suna da barazanar rai.

Mai zuwa jerin manyan magungunan da ake karantawa don sabon coronavirus:

1. Ivermectin

Ivermectin wani yanki ne wanda aka nuna don maganin cututtukan ƙwayoyin cuta, waɗanda ke haifar da matsaloli kamar onchocerciasis, elephantiasis, pediculosis (ƙwarƙwata), ascariasis (roundworms), scabies ko hanji strongyloidiasis kuma wanda, kwanan nan, ya nuna sakamako mai kyau a cikin kawar da cutar coronavirus sabuwa, cikin vitro.

Nazarin da aka gudanar a Ostiraliya, an gwada ivermectin a cikin dakin gwaje-gwaje, a cikin al'adun ƙwayoyin halitta cikin vitro, kuma an gano cewa wannan sinadarin ya iya kawar da kwayar ta SARS-CoV-2 cikin awanni 48 ^[7]. Koyaya, ana buƙatar gwaji na asibiti a cikin mutane don tabbatar da ingancinta a cikin rayuwa, kazalika da maganin warkewa da amincin magani, wanda ake tsammanin zai faru a tsakanin tsakanin watanni 6 zuwa 9.

Bugu da ƙari, wani binciken ya nuna cewa yin amfani da ivermectin ta marasa lafiya da aka gano tare da COVID-19 na wakiltar raguwar haɗarin rikice-rikice da ci gaban cuta, yana nuna cewa ivermectin na iya inganta hangen nesa na cutar ^[33]. A lokaci guda, binciken da aka gudanar a Bangladesh ya nuna cewa amfani da ivermectin (12 MG) na tsawon kwanaki 5 yana da tasiri da aminci a cikin maganin COVID-19 ^[34].

A cikin Nuwamba 2020 ^[35] zato na masu binciken Indiya cewa ivermectin zai iya tsoma baki tare da jigilar kwayar cutar zuwa cibiyoyin kwayar halitta, hana ci gaban kamuwa da cutar, an buga shi a cikin mujallar kimiyya, amma wannan tasirin zai yiwu ne kawai tare da yawan allurai ivermectin, wanda zai iya zama mai guba ga jikin ɗan adam.

Wani binciken da aka fitar a watan Disamba na 2020 ^[36] Hakanan ya nuna cewa yin amfani da sinadarin nanoparticles mai dauke da ivermectin zai iya rage bayyanar kwayoyin kwayoyin 'ACE2 masu karba, yana rage yiwuwar kwayar cutar ta daure ga wadannan masu karban cutar da kuma haifar da kamuwa da cuta. Koyaya, wannan binciken anyi shi ne kawai a cikin vitro, kuma bazai yiwu a faɗi cewa sakamakon zai zama iri ɗaya ba a cikin rayuwa. Bugu da kari, tunda wannan sabon salon magani ne, karatun gubar sun zama dole.

Duk da wannan sakamakon, ana buƙatar ƙarin nazari don nuna tasirin ivermectin a cikin maganin COVID-19, da kuma tasirin sa wajen hana kamuwa da cuta. Duba ƙarin game da amfani da ivermectin akan COVID-19.

Yuli 2, 2020 Sabuntawa:

Hukumar Kula da Magunguna ta Yankin São Paulo (CRF-SP) ta fitar da bayanin fasaha ^[20] wanda a ciki yake cewa maganin ivermectin yana nuna aikin antiviral a wasu nazarin in-vitro, amma ana buƙatar ci gaba da bincike don la'akari da cewa ana iya amfani da ivermectin cikin aminci cikin mutane game da COVID-19.

Don haka, yana ba da shawara cewa sayar da ivermectin ya kamata a yi shi kawai tare da gabatar da takardar likita da kuma cikin allurai da lokutan da likita ya umurta.

Yuli 10, 2020 Sabuntawa:

Dangane da bayanin bayani da ANVISA ya fitar ^[22], babu wani cikakken bincike wanda ya tabbatar da amfani da ivermectin don maganin COVID-19, kuma amfani da magani don magance kamuwa da cuta tare da sabon coronavirus ya zama alhakin likitan da ke jagorantar maganin.

Bugu da kari, sakamakon farko da aka fitar ta hanyar binciken da Cibiyar USP ta Kimiyyar Kimiyyar Kimiyyar Kimiyyar Kimiyyar Kimiyya (ICB) ^[23], nuna cewa ivermectin, kodayake yana iya kawar da kwayar cutar daga kwayoyin cutar a cikin dakin binciken, amma kuma yana haifar da mutuwar waɗannan ƙwayoyin, wanda na iya nuna cewa wannan maganin bazai zama mafi kyawun maganin magani ba.

Sabunta Disamba 9, 2020:

A cikin wani daftarin aiki da Brazilianungiyar ofungiyar Masu Yaɗuwar Cututtuka ta Brazil (SBI) ta fitar ^[37] an nuna cewa babu wani shawarwari game da magani na farko da / ko maganin rigakafi don COVID-19 tare da kowane magani, gami da ivermectin, tunda binciken asibiti na bazuwar da aka gudanar har yanzu ba ya nuna fa'idodi kuma, gwargwadon sashi, da aka yi amfani da shi, na iya a haɗa shi da lahani wanda zai iya haifar da illa ga lafiyar mutum.

Sabunta Fabrairu 4, 2021:

Merck, wanda shi ne kamfanin harhada magunguna da ke da alhakin samar da maganin Ivermectin, ya nuna cewa a cikin binciken da aka yi bai gano wata shaidar kimiyya da ke nuna karfin maganin wannan magani a kan COVID-19 ba, kuma ba ta gano wani tasiri a marasa lafiya ba tuni an gano yana dauke da cutar.

2. Maganin Plitidepsin

Plitidepsin magani ne na maganin kumburi wanda aka samar daga dakin gwaje-gwaje na Spain wanda aka nuna don maganin wasu lokuta na myeloma mai yawa, amma wanda kuma yana da tasirin rigakafin cutar kan sabon coronavirus.

Dangane da binciken da aka yi a Amurka ^[39], plitidepsin ya iya rage nauyin kwayar cutar coronavirus har zuwa 99% a cikin huhun berayen dakin gwaje-gwaje da suka kamu da COVID-19. Masu bincike sun ba da hujjar nasarar kwayar cikin iyawarta na toshe wani furotin da ke cikin kwayoyin halitta wadanda ke da muhimmanci kwayar cutar ta ninka kuma ta yadu cikin jiki.

Waɗannan sakamakon, tare da gaskiyar cewa an riga an yi amfani da maganin a cikin mutane don maganin myeloma da yawa, suna ba da shawarar cewa maganin yana da lafiya da za a gwada shi a cikin marasa lafiyar mutum da ke ɗauke da COVID-19. Don haka, ya zama dole a jira sakamakon waɗannan gwaje-gwaje na asibiti don fahimtar sashi da yiwuwar guba na magani.

3. Remdisivir

Wannan magani ne mai yaduwa sosai wanda aka kirkireshi don magance cutar ta Ebola, amma bai nuna sakamako mai kyau kamar sauran abubuwa ba. Koyaya, saboda fa'idar da take da shi akan ƙwayoyin cuta, ana yin nazari don fahimtar idan zata iya gabatar da sakamako mai kyau a cikin kawar da sabon kwayar cutar.

Nazarin farko da aka yi a dakin gwaje-gwaje tare da wannan magani, duka a cikin Amurka ^{[1] [2]}, kamar a China ^[3], ya nuna sakamako mai kyau, tunda abun ya iya hana yaduwa da narkar da sabon coronavirus, da kuma sauran ƙwayoyin cuta na dangin coronavirus.

Koyaya, kafin a ba da shawara a matsayin nau'i na magani, wannan magani yana buƙatar yin karatu da yawa tare da mutane, don fahimtar ingancinsa da amincinsa na gaskiya. Don haka, a halin yanzu, game da karatun 6 da ake gudanarwa tare da adadi mai yawa na marasa lafiya da suka kamu da COVID-19, duka a cikin Amurka, a Turai da Japan, amma ya kamata a saki sakamakon kawai a cikin Afrilu , a yanzu, babu wata hujja da ta nuna cewa Remdesivir, a zahiri, ana iya amfani dashi lafiya don kawar da sabon kwayar cutar corona a cikin mutane.

Afrilu 29, 2020 Sabuntawa:

Dangane da binciken Kimiyyar Gilead ^[8], a Amurka, yin amfani da Remdesivir a cikin marasa lafiya tare da COVID-19 da alama yana gabatar da sakamako iri ɗaya a cikin lokacin shan magani na kwanaki 5 ko 10, kuma a cikin duka maganganun an sallami marasa lafiya daga asibiti a cikin kusan kwanaki 14 da kuma abin da ya faru Hakanan illoli basu da yawa. Wannan binciken ba ya nuna darajar tasirin magani don kawar da sabon kwayar cutar coronavirus kuma, sabili da haka, ana yin sauran binciken.

Mayu 16, 2020 Sabuntawa:

Nazarin a kasar Sin kan marasa lafiya 237 da ke dauke da mummunar cutar ta COVID-19 ^[15] ya ba da rahoton cewa marasa lafiyar da aka bi da wannan maganin sun nuna saurin warkewa idan aka kwatanta da masu kula da cutar, tare da matsakaita na kwanaki 10 idan aka kwatanta da kwanaki 14 da ƙungiyar ta gabatar tare da placebo.

Sabunta Mayu 22, 2020:

Rahoton farko na wani binciken da aka gudanar a Amurka tare da Remdesivir ^[16] Har ila yau, ya nuna cewa yin amfani da wannan magani yana da alamar rage lokacin murmurewa a cikin manya da ke asibiti, kazalika don rage haɗarin ƙananan kamuwa da cuta na numfashi.

Sabunta Yuli 26, 2020:

Dangane da binciken da Makarantar Kiwon Lafiyar Jama'a ta Jami'ar Boston ^[26], remdesivir yana rage lokacin magani a marasa lafiya da aka shigar dasu ICU.

Nuwamba 5, 2020 Sabuntawa:

Rahoton ƙarshe na binciken da ake yi a Amurka tare da Remdesivir ya nuna cewa yin amfani da wannan magani yana, a zahiri, yana rage matsakaicin lokacin murmurewa a cikin manya masu asibiti, daga 15 zuwa 10 kwanakin ^[31].

Nuwamba 19, 2020 Sabuntawa:

FDA a Amurka ta ba da izinin gaggawa ^[32] wanda ke ba da damar amfani da Remdesivir tare da magani Baricitinib, a cikin kula da marasa lafiya da ke fama da cutar coronavirus mai tsanani kuma suna buƙatar oxygenation ko iska.

Nuwamba 20, 2020 Sabuntawa:

Hukumar ta WHO ta ba da shawara kan amfani da Remdesivir wajen kula da masu fama da cutar ta COVID-19 saboda rashin cikakkun bayanai da ke nuna cewa Remdesivir yana rage yawan mace-macen.

4. Dexamethasone

Dexamethasone wani nau'in corticosteroid ne wanda ake amfani dashi a cikin marasa lafiya tare da matsaloli na numfashi na yau da kullun, kamar asma, amma kuma ana iya amfani dashi a cikin wasu matsalolin kumburi, kamar cututtukan zuciya ko kumburin fata. An gwada wannan magani a matsayin hanya don rage alamun COVID-19, saboda yana iya taimakawa rage ƙonewa cikin jiki.

Dangane da binciken da ake yi a Burtaniya ^[18], dexamethasone ya bayyana shine magani na farko da aka gwada don rage yawan mace-macen marasa lafiya masu cutar tare da COVID-19. Dangane da sakamakon binciken, dexamethasone ya samu nasarar rage yawan mace-macen har zuwa kwanaki 28 bayan kamuwa da sabon kwayar ta corona, musamman a mutanen da ke bukatar a taimaka musu da na’urar shakar iska ko gudanar da iskar oxygen.

Yana da mahimmanci a tuna cewa dexamethasone baya kawar da kwayar kwayar cuta daga jiki, yana taimakawa ne kawai don taimakawa bayyanar cututtuka da kuma guje wa matsaloli masu tsanani.

Yuni 19, 2020 Sabuntawa:

Brazilianungiyar Brazilianungiyar ofwararrun Brazilianwararrun Brazilianwararru ta Brazil ta ba da shawarar yin amfani da dexamethasone na kwanaki 10 don kula da duk marasa lafiya tare da COVID-19 da aka shigar da su ICU tare da iska ta injuna ko kuma waɗanda suke buƙatar karɓar iskar oxygen. Koyaya, bai kamata ayi amfani da corticosteroids a cikin yanayi mai sauƙi ba ko kuma hanyar hana kamuwa da cuta ^[19].

Sabunta Yuli 17, 2020:

Dangane da binciken kimiyya da aka gudanar a theasar Ingila ^[24], magani tare da dexamethasone na kwanaki 10 a jere kamar zai rage yawan mace-macen da ke fama da cutar mai tsanani ta hanyar sabon kwayar cutar, wacce ke bukatar iska. A waɗannan yanayin, yawan mace-mace ya bayyana ya ragu daga 41.4% zuwa 29.3%. A cikin sauran marasa lafiya, tasirin magani tare da dexamethasone bai nuna irin wannan sakamakon alamun ba.

Sabunta Satumba 2, 2020:

A meta-bincike dangane da gwajin gwaji na 7 ^[29] Ya ƙare da cewa amfani da dexamethasone da sauran corticosteroids na iya, a zahiri, rage mace-mace a cikin majiyyatan cututtukan da ke ɗauke da COVID-19.

Sabunta Satumba 18, 2020:

Hukumar Kula da Magunguna ta Turai (EMA) ^[30] ya yarda da amfani da dexamethasone wajen kula da matasa da manya da suka kamu da sabon coronavirus, waɗanda ke buƙatar tallafin oxygen ko kuma iska ta iska.

5. Hydroxychloroquine da chloroquine

Hydroxychloroquine, da chloroquine, abubuwa ne guda biyu waɗanda ake amfani dasu wajan kula da marasa lafiya da zazzaɓin cizon sauro, lupus da wasu matsaloli na musamman na kiwon lafiya, amma har yanzu ba'a ɗauke su da aminci a duk yanayin COVID-19 ba.

Nazarin da aka gudanar a Faransa ^[4] kuma a China ^[5], ya nuna tasirin chloroquine da hydroxychloroquine a rage rage kwayar cuta da rage safarar kwayar a cikin kwayoyin halitta, rage karfin kwayar cutar ta ninka, don haka, a dawo da sauri. Koyaya, waɗannan karatun anyi su akan ƙananan samfuran kuma ba duk gwaje-gwajen bane tabbatattu.

A yanzu, a cewar Ma'aikatar Lafiya ta Brazil, ana iya amfani da maganin chloroquine ne kawai a cikin mutanen da aka shigar da su asibiti, tsawon kwanaki 5, a karkashin kulawa ta dindindin, don tantance bayyanar illolin da ke tattare da cutar, kamar matsalolin zuciya ko canje-canje a hangen nesa .

Afrilu 4, 2020 Sabuntawa:

Ofaya daga cikin karatun da ke gudana, tare da haɗin amfani da hydroxychloroquine da maganin azithromycin na rigakafi ^[9], a Faransa, an gabatar da sakamako mai gamsarwa a cikin ƙungiyar marasa lafiya 80 tare da matsakaiciyar alamomin COVID-19. A cikin wannan rukunin, an gano raguwar tasirin kwayar sabon coronavirus a cikin jiki, bayan kimanin kwanaki 8 na jinya, wanda bai kai matsakaicin makonni 3 da mutanen da ba su sha wani magani na musamman ba.

A cikin wannan binciken, daga cikin marasa lafiya 80 da aka yi nazari, mutum 1 ne kawai ya mutu, saboda da an shigar da shi asibiti a wani matakin ci gaba sosai na kamuwa da cutar, wanda ƙila ya hana magani.

Wadannan sakamakon suna ci gaba da tallafawa ka'idar cewa amfani da hydroxychloroquine na iya zama hanya mai aminci don magance kamuwa da cutar COVID-19, musamman a lokuta na alamomi masu sauƙi zuwa matsakaici, ban da rage haɗarin kamuwa da cuta. Har yanzu, ya zama dole a jira sakamakon sauran karatun da ake gudanarwa tare da magani, don samun sakamako tare da samfurin yawan jama'a.

Afrilu 23, 2020 Sabuntawa:

Majalisar Kula da Magunguna ta Tarayyar Brazil ta amince da amfani da Hydroxychloroquine a hade tare da Azithromycin bisa shawarar likitan, a cikin marasa lafiya masu fama da rauni ko matsakaiciyar alamomi, amma waɗanda ba sa buƙatar shigar da ICU, wanda sauran cututtukan ƙwayoyin cuta, kamar su Influenza ko H1N1 , kuma an tabbatar da ganewar asali na COVID-19 ^[12].

Don haka, saboda rashin sakamako mai ƙarfi na kimiyya, wannan haɗin magungunan ya kamata a yi amfani dashi kawai tare da yardar mai haƙuri da kuma shawarar likitan, bayan tantance haɗarin da ke iya faruwa.

Mayu 22, 2020 Sabuntawa:

Dangane da binciken da aka gudanar a Amurka tare da marasa lafiya 811 ^[13], yin amfani da Chloroquine da Hydroxychloroquine, hade ko ba azithromycin ba, ba ze haifar da sakamako mai amfani ba a cikin maganin COVID-19, har ma da alama ya ninka yawan mace-macen marasa lafiya, tunda waɗannan kwayoyi suna ƙara haɗarin matsalolin rikicewar zuciya, musamman arrhythmia da atr fibrillation.

Ya zuwa yanzu, wannan shine babban binciken da aka yi tare da hydroxychloroquine da chloroquine. Tun da sakamakon da aka gabatar ya saba wa abin da aka faɗi game da waɗannan magungunan, har yanzu ana buƙatar ci gaba da karatu.

Mayu 25, 2020 Sabuntawa:

Hukumar Lafiya ta Duniya (WHO) ta dakatar da bincike na dan lokaci kan sinadarin hydroxychloroquine da ta tsara a kasashe da dama. Yakamata a dakatar da dakatarwar har sai an sake tantance lafiyar miyagun ƙwayoyi.

Mayu 30, 2020 Sabuntawa:

Jihar Espírito Santo, a cikin Brazil, ta janye alamar amfani da maganin chloroquine a cikin marasa lafiya da COVID-19 a cikin mawuyacin hali.

Bugu da kari, masu gabatar da kara daga Ma’aikatar Jama’a ta Tarayya na São Paulo, Rio de Janeiro, Sergipe da Pernambuco suna neman a dakatar da dokokin da ke nuna amfani da sinadarin hydroxychloroquine da chloroquine wajen kula da marasa lafiya da COVID-19.

Yuni 4, 2020 Sabuntawa:

Mujallar Lancet ta janye wallafar nazarin marasa lafiya 811 wadanda suka nuna cewa amfani da sinadarin hydroxychloroquine da chloroquine ba shi da wani fa'ida ga maganin COVID-19, saboda wahalar samun bayanan farko da aka gabatar a binciken.

Yuni 15, 2020 Sabuntawa:

FDA, wacce ita ce babbar hukumar kula da magunguna ta Amurka, ta janye izinin gaggawa don amfani da chloroquine da hydroxychloroquine wajen kula da COVID-19 ^[17], gaskata babban matakin haɗarin ƙwayoyi da ƙananan ƙarancin ƙarfi don maganin sabuwar kwayar cutar corona.

Sabunta Yuli 17, 2020:

Brazilianungiyar ta Brazil ta Cututtuka ^[25] ya bada shawarar cewa a bar amfani da hydroxychloroquine a cikin maganin COVID-19, a kowane mataki na kamuwa da cutar.

Yuli 23, 2020 Sabuntawa:

A cewar wani binciken na Brazil ^[27], anyi aiki tare tsakanin Albert Einstein, HCor, Sírio-Libanês, Moinhos de Vento, Oswaldo Cruz da Beneficência Portuguesa Asibitocin, amfani da hydroxychloroquine, mai alaƙa ko ba tare da azithromycin ba, da alama ba shi da wani tasiri a cikin maganin masu kamuwa da cutar matsakaiciya marasa lafiya tare da sabon coronavirus.

6. Colchicine

Dangane da binciken da aka gudanar a Kanada ^[38], colchicine, magani da ake amfani dashi sosai wajen magance matsalolin rheumatological, kamar su gout, na iya taimakawa wajen maganin marasa lafiya da COVID-19.

A cewar masu binciken, kungiyar marasa lafiyar da aka yi wa wannan magani tun lokacin da aka gano cutar, idan aka kwatanta da kungiyar da ta yi amfani da maganin wuribo, sun nuna raguwar kasadar kamuwa da mummunar cutar. Bugu da kari, an kuma bayar da rahoton raguwa a asibiti da kuma yawan mace-macen.

7. Mefloquine

Mefloquine magani ne da aka nuna don rigakafi da maganin zazzabin cizon sauro, a cikin mutanen da ke da niyyar tafiya zuwa yankunan da ke fama da cutar. Dangane da karatun da aka yi a China da Italiya^[6], wani tsarin magani wanda ake hada mefloquine tare da wasu magunguna ana nazarin shi a Rasha don tabbatar da ingancin sa wajen shawo kan cutar COVID-19, amma har yanzu babu wani sakamako tabbatacce.

Don haka, ba a ba da shawarar amfani da mefloquine don magance kamuwa da sabon coronavirus saboda ana buƙatar ƙarin karatu don tabbatar da inganci da amincin sa.

8. Tocilizumab

Tocilizumab magani ne wanda ke rage aikin tsarin garkuwar jiki kuma, sabili da haka, yawanci ana amfani dashi don kula da marasa lafiya da cututtukan zuciya na rheumatoid, don rage haɓakar maganin rigakafi, rage kumburi da sauƙaƙe alamun.

Ana nazarin wannan magani don taimakawa wajen kula da COVID-19, musamman a cikin matakan ci gaba na kamuwa da cuta, lokacin da akwai adadi mai yawa na abubuwa masu kumburi da ƙwayoyin cuta ke samarwa, wanda zai iya ɓata yanayin asibiti.

A cewar wani bincike a kasar Sin ^[10] a cikin marasa lafiya 15 da suka kamu da cutar COVID-19, yin amfani da tocilizumab ya tabbatar da cewa ya fi tasiri da haifar da ƙananan sakamako masu illa, idan aka kwatanta da corticosteroids, waɗanda sune magungunan da ake amfani dasu gaba ɗaya don sarrafa kumburi da aka samu ta hanyar ba da kariya.

Har yanzu, ana buƙatar gudanar da ƙarin karatu, don fahimtar menene mafi kyawun magani, ƙayyade tsarin kulawa da gano menene tasirin illa.

Afrilu 29, 2020 Sabuntawa:

A cewar wani sabon binciken da aka yi a kasar Sin tare da marasa lafiya 21 da suka kamu da COVID-19^[14], magani tare da tocilizumab ya bayyana zai iya rage alamun kamuwa da cutar ba da jimawa ba bayan gudanar da maganin, rage zazzabi, sauƙaƙa jin matsi a cikin kirji da inganta matakan oxygen.

An gudanar da wannan binciken ne a cikin marasa lafiya masu tsananin alamun cutar kuma ya ba da shawarar cewa ya kamata a fara magani da tocilizumab da wuri-wuri lokacin da mai haƙuri ya fita daga matsakaiciyar yanayi zuwa mummunan yanayin kamuwa da sabon coronavirus.

Sabunta Yuli 11, 2020:

Sabon bincike na Jami’ar Michigan da ke Amurka ^[28], ya kammala da cewa amfani da tocilizumab a cikin marassa lafiya tare da COVID-19 ya bayyana ne don rage yawan mace-macen marasa lafiya da ke samun iska, kodayake ya kara barazanar kamuwa da wasu cututtukan.

9. Plasma mai naƙasa

Plasma na Convalescent wani nau'in magani ne na halitta wanda ake daukar samfurin jini, daga mutanen da suka riga suka kamu da kwayar ta coronavirus kuma wadanda aka warke, wadanda daga nan suke shan wasu hanyoyin shawo kan cutar don raba jini da jinin ja. A ƙarshe, wannan allurar an yi mata allura a cikin mara lafiyar don taimaka wa garkuwar jiki ta yaƙi ƙwayoyin cutar.

Ka'idar da ke bayan wannan magani ita ce, kwayoyin cuta da jikin wanda ya kamu da cutar ya samar, kuma ya rage a cikin jini, ana iya canza shi zuwa jinin wani wanda har yanzu yana dauke da cutar, yana taimakawa karfafawa Yanayin rigakafi da saukaka kawar da kwayar.

Dangane da Bayanin Fasaha mai lamba 21 da Anvisa ya fitar, a cikin Brazil, ana iya amfani da plasma mai haɗuwa a matsayin gwajin gwaji ga marasa lafiyar da ke kamuwa da sabon kwayar ta corona, matuƙar ana bin duk dokokin Kula da Lafiya. Bugu da kari, duk shari'ar da ke amfani da plasma mai nakasa don maganin COVID-19 dole ne a sanar da shi zuwa ga Janar Gudanar da Kayan Jini da Jini na Ma'aikatar Lafiya.

10. Avifavir

Avifavir magani ne da aka samar a Rasha wanda kayan aikin sa shine favipiravir, wanda a cewar Asusun Asusun Zuba Jari na Rasha (RDIF) ^[21] yana da ikon magance kamuwa da kwayar cutar, bayan an haɗa shi cikin ladabi da rigakafin rigakafin COVID-19 a Rasha.

Dangane da binciken da ake gudanarwa, a cikin kwanaki 10, Avifavir ba shi da wani sabon sakamako na illa kuma, a cikin kwanaki 4, 65% na marasa lafiyar da aka kula suna da gwaji mara kyau ga COVID-19.

11. Baricitinib

FDA ta ba da izinin yin amfani da gaggawa na maganin Baricitinib don magance manyan cututtukan COVID-19 ^[32]a hade tare da Remdesivir. Baricitinib wani abu ne wanda yake rage amsawar garkuwar jiki, yana rage aikin enzymes wanda ke inganta kumburi kuma anyi amfani dashi a baya a cikin cututtukan rheumatoid.

A cewar Hukumar ta FDA, ana iya amfani da wannan haɗin ga marasa lafiyar manya da yara da suka girmi shekaru 2, suna asibiti kuma suna buƙatar magani tare da iskar oxygen ko kuma iska ta iska.

12. EXO-CD24

EXO-CD24 magani ne da aka nuna don maganin kansar mahaifa kuma ya sami damar warkar da marasa lafiya 29 daga 30 tare da COVID-19. Koyaya, ana ci gaba da gudanar da karin karatu, tare da adadi mai yawa na mutane, tare da haƙiƙanin tabbatarwa ko wannan magani zai yi tasiri a maganin cutar da kuma ƙimar da aka ɗauka amintacce don amfani.

Zaɓuɓɓukan maganin gargajiya don coronavirus

Ya zuwa yanzu babu wasu tabbatattun magunguna na zahiri don kawar da kwayar corona da taimakawa warkar da COVID-19, amma, WHO ta fahimci cewa tsiron Artemisia shekara zai iya taimaka tare da magani ^[11], musamman a wuraren da samun magunguna ya fi wahala kuma ana amfani da tsire-tsire a maganin gargajiya, kamar yadda ake yi a yankuna daban-daban na Afirka.

Ganyen shukar Artemisia shekara ana amfani da su a al'ada a Afirka don taimakawa maganin malaria kuma, don haka, WHO ta gane cewa akwai buƙatar karatu don fahimtar ko ana iya amfani da tsire-tsire don kula da COVID-19, tun da wasu magungunan roba akan zazzaɓin ma sun nuna kyakkyawan sakamako. .

Duk da haka, yana da mahimmanci a tuna cewa ba a tabbatar da amfani da shuka ba akan COVID-19 kuma ana buƙatar ƙarin bincike.